NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.

Guide: Setting the Stage for a Fit-For-Purpose DTx Evidentiary Standard

Get the white paper

Curebase has worked closely with the Digital Therapeutics Alliance (DTA) in the development of their newest whitepaper: Setting the Stage for a Fit-For-Purpose DTx Evidentiary Standard. 

This first-of-its-kind, highly reviewed whitepaper outlines foundational principles specific to digital therapeutics research including baseline expectations related to the types, quality, and timing of clinical trials necessary to evaluate and implement digital therapies in real-world settings.

A fit-for-purpose evidence standard more cohesively addresses the unique needs of DTx clinical trials and further clarifies and demonstrates proper care standards and expectations.

This paper will cover:

  • Foundational principles specific to the DTx category of medicine related to the types, quality, and timing of clinical trials
  • A harmonized, consistent set of study expectations to sufficiently demonstrate product safety, efficacy, and impact for DTx
  • Evidence-based expectations for how DTx products should be validated by payors globally
  • And more

Find a time to chat with us

We'd love to hear from you, whether a sponsor or CRO interested in running a study with us. After filling out and submitting this form, you will be taken to a calendar where you can choose a meeting time convenient for you.

All other inquiries please send to hello@curebase.com

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States